MedX Health Announces Patent Allowance for Use of Laser and Light Probe for Bone Healing



    
    Notice of Allowance Covers Laser and Light Therapy Apparatus and Method
    for Bone Healing, Bone Growth Stimulation and Bone Cartilage Regeneration
    

    MISSISSAUGA, ON, Feb. 23 /CNW/ - MedX Health Corp., (TSXV.MDX) a global
leader in developing drug free, non-invasive low level laser and light therapy
for tissue repair and pain relief, today announced that the company has
received a Notice of Allowance by the United States Patent & Trademark Office
for its MedX Laser and Light Probe use and method for bone healing, bone
growth stimulation and bone cartilage regeneration. The allowed claims cover
the use of MedX's laser and light unit and the use of light therapy in various
bone and cartilage healing situations such as carpal tunnel syndrome,
tendonitis, bone growth and regeneration following a break, rheumatoid
arthritis and wound healing.
    "This notice of allowance from the U.S. Patent & Trademark Office
broadens our device portfolio," states Steve Guillen, president and CEO of
MedX Health. "It is another important step toward our entry into the wound
healing market, which we expect will take place this year," adds Guillen.
    The use of low level lasers and light therapy has been documented to be
effective in promoting healing of bone, muscle, cartilage, tendon and
ligaments. The newly allowed claims will cover The MedX Laser and Light Probe
and its use in the treatment of damaged bone and cartilage. Specifically, the
probe emits light, which triggers biological changes within the body,
stimulating and accelerating cellular metabolic processes. The process of
utilizing the MedX Laser and Light Probe increases the circulation by
formulating new capillaries, and also stimulates collagen protein production,
thus accelerating the healing process by helping damaged bone cells and tissue
replace themselves more rapidly.

    About MedX

    MedX Health is a global leader in the design, manufacturing and
distribution of quality low level laser and light therapy technology for use
in numerous medical settings that provide patients with non-invasive,
drug-free solutions for improving clinical outcomes. MedX's innovative
Laser/Light Therapy devices enhance the rehabilitation process and are
effective in pain relief, the rapid healing of tissue and bone damage, and may
help patients overcome their addiction to drugs, alcohol or tobacco.
    MedX is expanding its distribution network and marketing program globally
through strategic partnerships, while continuing to develop and acquire new
dental, rehabilitation and wound care products. In particular, MedX plans to
accelerate the development of a new product aimed at the rapidly-growing wound
care market. The newest patent allowance for bone growth joins several key
existing patents, including "Photobandage", a new technology that allows a
wound to be bathed in light and is designed to enhance the healing process.
The Company intends to license their wound care technologies to one or more
major wound care companies for further development, marketing and
commercialization.

    
    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this press release.
    

    This press release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. Such forward-looking
information may include statements regarding the Company's future plans,
objectives, performance, growth, profits, operating expenses or its underlying
assumptions. Generally, forward-looking information can be identified by the
use of forward-looking terminology such as "plans", "expects", or "does not
expect", "is expected", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates", or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", or "will be taken", "occur", or "be
achieved". Forward-looking information is subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of MedX to be materially different from
those expressed or implied by such forward-looking information, including
uncertainty of successful development of new products, uncertainty of
successful manufacturing or marketing of products, uncertainty of commercial
acceptance of products, uncertainty concerning governmental regulation,
dependency on key employees and relationships, rapid technological changes,
foreign currency fluctuations. MedX does not undertake to update any
forward-looking information, except in accordance with applicable securities
laws.

    %SEDAR: 00017466E




For further information:

For further information: Investors: Steve Guillen, President and Chief
Executive Officer, MedX Health Corp., Phone: (905) 826-0766,
info@medxhealth.com; Media: Terri Clevenger, Continuum Health Communications,
Phone (203) 227-0209, Email: tclevenger@continuumhealthcom.com

Organization Profile

MedX Health Corp.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890